OTCMKTS:MAQAF Atlas Arteria (MAQAF) Stock Price, News & Analysis $3.08 0.00 (0.00%) As of 10/1/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Atlas Arteria Stock (OTCMKTS:MAQAF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atlas Arteria alerts:Sign Up Key Stats Today's Range$3.08▼$3.0850-Day Range$3.08▼$3.6852-Week Range$2.69▼$4.09VolumeN/AAverage Volume1,235 shsMarket CapitalizationN/AP/E RatioN/ADividend Yield2.69%Price Target$5.03Consensus RatingHold Company Overview Atlas Arteria (OTCMKTS:MAQAF) is an international toll-road owner and operator headquartered in Australia. Through its portfolio of infrastructure investments, the company manages and operates road networks that generate revenue from electronic and conventional tolling, while providing motorists with access to major transport corridors. The company’s principal interests include toll-road assets in France, Germany and the United States. Its French operations include interests in the APRR and AREA motorway networks, which connect major cities and commercial regions across eastern and southeastern France. Atlas Arteria has also owned or operated assets such as the Warnow Tunnel in Germany and the Dulles Greenway in Virginia. Its portfolio has changed over time as the company has pursued asset sales and other strategic transactions. Atlas Arteria was established as Macquarie Atlas Roads in 2005 and adopted its current name in 2018. The company focuses on the long-term ownership, development and operation of transportation infrastructure, with an emphasis on maintaining road availability, improving customer service and supporting efficient movement of people and goods.AI Generated. May Contain Errors. Read More Atlas Arteria Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreMAQAF MarketRank™: Atlas Arteria scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingAtlas Arteria has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialAtlas Arteria has a consensus price target of $5.03, representing about 63.3% upside from its current price of $3.08.Amount of Analyst CoverageAtlas Arteria has only been the subject of 1 research reports in the past 90 days.Read more about Atlas Arteria's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Atlas Arteria is -29.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atlas Arteria is -29.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares ShortedShort Interest Ratio / Days to CoverAtlas Arteria has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.Change versus previous monthShort interest in Atlas Arteria has recently decreased by 7.94%, indicating that investor sentiment is improving significantly. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipAtlas Arteria is a leading dividend payer. It pays a dividend yield of 5.02%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAtlas Arteria does not have a long track record of dividend growth.Read more about Atlas Arteria's dividend. News and Social MediaN/ANews SentimentN/A Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atlas Arteria insiders have not sold or bought any company stock.Percentage Held by Institutions24.06% of the stock of Atlas Arteria is held by institutions.Read more about Atlas Arteria's insider trading history. Receive MAQAF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atlas Arteria and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAQAF Stock News HeadlinesPositive Report for Atlas Arteria (MAQAF) from JefferiesSeptember 6, 2026 | theglobeandmail.comMorgans Remains a Hold on Atlas Arteria (MAQAF)August 28, 2026 | theglobeandmail.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.October 2 at 1:00 AM | Behind the Markets (Ad)Atlas Arteria H1 2026 earnings: profit swings on one-offs, guidance heldAugust 26, 2026 | fool.com.auAnalysts Conflicted on These Industrial Goods Names: ALS (OtherCPBLF) and Atlas Arteria (OtherMAQAF)July 31, 2026 | theglobeandmail.comAtlas Arteria Q2 2026 earnings: Stable toll revenues, new debt facility boosts liquidityJuly 28, 2026 | msn.comEnd of the road: How IFM finally broke Atlas ArteriaJune 22, 2026 | afr.comAtlas Arteria in talks to sell German toll road to stymie IFMJune 22, 2026 | afr.comSee More Headlines MAQAF Stock Analysis - Frequently Asked Questions How have MAQAF shares performed this year? Atlas Arteria's stock was trading at $2.84 at the beginning of 2026. Since then, MAQAF stock has increased by 8.5% and is now trading at $3.08. How do I buy shares of Atlas Arteria? Shares of MAQAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorIndustrials Industry Infrastructure Operations Sub-IndustryN/A Current SymbolOTCMKTS:MAQAF CIKN/A Webwww.atlasarteria.com Phone611800621694FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Atlas Arteria$5.03 High Price Target$5.31 Low Price Target$4.75 Potential Upside/Downside+63.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:MAQAF) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg termi...Chaikin Analytics | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredWATCH THIS BEFORE DECEMBER 8th!!James Altucher says a quiet government filing could reveal Elon Musk's biggest move yet, and almost nobody has...Paradigm Press | SponsoredA new kind of civil war is coming after election day?Across America, AI-driven backlash is fueling protests, lawsuits, and moratoria that could reshape the politic...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atlas Arteria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Atlas Arteria With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.